CEO: Sujal Shah

Sector: Health Technology
Industry:Biotechnology

Exchange: NASDAQ

Country: US

Description: CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.


Key numbers

Market Capitalization:243153460
Shares Outstanding: 68882000
Float: 66224050
Next Earning Date:2020-08-06
TTm EPS: -1.3503
TTm Dividend Rate:
200 days moving average:2.78
50 days moving average: 3.74
One day percent Change: 37.46



2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,
2015-12-31, 2016-12-31, 2017-12-31, 2018-12-31,